Stereotactic body radiation therapy for gastrointestinal malignancies

Frontiers of Radiation Therapy and Oncology

Volumn 43, Issue , 2011, Pages 412-427

  Minn, A Yuriko ^a   Koong, Albert C ^a   Chang, Daniel T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PRACTICE; COLORECTAL CANCER; CRYOABLATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSIMETRY; DUODENUM BLEEDING; DUODENUM CANCER; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; LETHARGY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TUMOR; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOFREQUENCY ABLATION; RIB FRACTURE; SMALL INTESTINE OBSTRUCTION; STANDARDIZATION; STEREOTACTIC BODY RADIATION THERAPY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; RADIOSURGERY;

CHEMOTHERAPY; DISEASE CONTROL; DISEASES; TOXICITY; TUMORS;

CLOSE PROXIMITY; FRACTIONATION SCHEDULES; IMAGE GUIDANCES; NORMAL TISSUE; OPTIMAL STRATEGIES; PANCREAS CANCER; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC BODY RADIOTHERAPY;

RADIOTHERAPY;

EID: 79958188244     PISSN: 00719676     EISSN: 16623789     Source Type: Book Series    
DOI: 10.1159/000322505     Document Type: Article

References (38)

1. Timmerman RD, Kavanagh BD, Cho LC, et al: Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007; 25: 947-952. (Pubitemid 350002860)
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Sener SF, Fremgen A, Menck HR, et al: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985- 1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7. (Pubitemid 29307735)
4. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
5. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80: 751-755.
6. Willett CG, Czito BG, Bendell JC, et al: Locally advanced pancreatic cancer. J Clin Oncol 2005; 23: 4538-4544. (Pubitemid 46196584)
7. Schellenberg D, Goodman KA, Lee F, et al: Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008; 72: 678-686.
8. Koong AC, Christofferson E, Le QT, et al: Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63: 320-323. (Pubitemid 41317146)
9. Koong AC, Le QT, Ho A, et al: Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1017-1021. (Pubitemid 38314781)
10. Chang DT, Schellenberg D, Shen J, et al: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009; 115: 665-672.
11. Hoyer M, Roed H, Sengelov L, et al: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005; 76: 48-53. (Pubitemid 41096514)
12. Murphy JD, Christman-Skieller C, Kim J, et al: A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010; 78: 1420-1426.
13. Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989; 16: 1623-1630. (Pubitemid 19154353)
14. Lyman JT: Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985; 8:S13-S19. (Pubitemid 16149302)
15. Bussels B, Goethals L, Feron M, et al: Respiration- induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol 2003; 68: 69-74. (Pubitemid 37289338)
16. Gierga DP, Chen GT, Kung JH, et al: Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys 2004; 58: 1584-1595. (Pubitemid 38438324)
17. Minn AY, Schellenberg D, Maxim P, et al: Pancreatic tumor motion on a single planning 4DCT does not correlate with intrafraction tumor motion during treatment. Am J Clin Oncol 2009; 32: 364-368.
18. Huguet F, Andre T, Hammel P, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331. (Pubitemid 350003022)
19. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
20. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358-1364.
21. Machi J, Oishi AJ, Sumida K, et al: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12: 318-326. (Pubitemid 44285559)
22. Siperstein AE, Berber E, Ballem N, et al: Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565, discussion 565-557. (Pubitemid 47480598)
23. Katz AW, Carey-Sampson M, Muhs AG, et al: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007; 67: 793-798. (Pubitemid 46215888)
24. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-1578.
25. Lee MT, Kim JJ, Dinniwell R, et al: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009; 27: 1585-1591.
26. Wulf J, Guckenberger M, Haedinger U, et al: Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006; 45: 838-847. (Pubitemid 44423130)
27. Hoyer M, Roed H, Traberg Hansen A, et al: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006; 45: 823-830. (Pubitemid 44423128)
28. Kavanagh BD, Schefter TE, Cardenes HR, et al: Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006; 45: 848-855. (Pubitemid 44423131)
29. Mendez Romero A, Wunderink W, Hussain SM, et al: Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006; 45: 831-837. (Pubitemid 44423129)
30. Nishioka T, Nishioka S, Kawahara M, et al: Synchronous monitoring of external/internal respiratory motion: validity of respiration-gated radiotherapy for liver tumors. Jpn J Radiol 2009; 27: 285-289.
31. Goodman KA, Wiegner EA, Maturen KE, et al: Dose escalation study of single fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010; 78: 486-493.
32. Tse RV, Hawkins M, Lockwood G, et al: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664. (Pubitemid 351264363)
33. Schefter TE, Kavanagh BD, Timmerman RD, et al: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005; 62: 1371-1378. (Pubitemid 40982057)
34. Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005; 15: 279-283. (Pubitemid 41377144)
35. Dawson LA, Eccles C, Craig T: Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol 2006; 45: 856-864. (Pubitemid 44423132)
36. Pettersson N, Nyman J, Johansson KA: Radiation- induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009; 91: 360-368.
37. Herfarth KK, Debus J, Lohr F, et al: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001; 19: 164-170. (Pubitemid 32063493)
38. Chang DT, Schellenberg DS, Koong AC: Nonhepatic gastrointestinal malignancies; in Timmerman RD, Xing L (eds): Image Guided and Adaptive Radiation Therapy. Philadelphia, Lippincott Williams & Wilkins, 2010, pp 225-232.